ASH 2016 Dr Rampal shares MPN updates on Clinical Research with PV Reporter

Ruxolitinib (Jakafi) plus PIM and CDK4/6 Inhibitors

First in ASH 2016 Series

by David Wallace

Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York City, presented pre-clinical data from a trial of a three drug combination in animal models in MPNs.  The combination of ruxolitinib, PIM447 ( a drug that targets PIM kinases) and LEE011 (a drug that targets the cell cycle by inhibiting CDK4/6) was effective at suppressing the growth of JAK2 mutant cells in vitro and in vivo.  The treatment reduced the allele burden somewhat and prevented the development of fibrosis.  The three-drug combo is currently being evaluated in a Phase 1 study.

About David Wallace

Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with “informed patients” and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward – “educating the patient is essential, so the patient can guide their physician to meet his or her needs.” PV Reporter is a comprehensive resource hub giving visitors vital tools to become “empowered patients.”

Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!